Novocure

Together with the National Brain Tumor Society (NBTS) and the brain tumor community at-large, we recently recognized the sixth annual #GlioblastomaAwarenessDay to raise national awareness about #glioblastoma (#GBM), the most common and deadliest type of brain cancer. Every year, thousands of Americans and their loved ones are affected by this aggressive form of cancer. At Novocure, we are grateful for continued partnership with patient advocacy organizations like the NBTS. We are also proud to serve as a sponsor for the organization’s annual GBM Awareness Day activities, which honor survivors and their loved ones and remember those who have lost their lives from this devastating disease. Each year on Capitol Hill, we’re grateful to join the NBTS as they bring together a bipartisan Congressional delegation to officially recognize the third Wednesday in July as #GBMDay. By raising awareness together, we are taking one step closer to achieving a future where GBM finally has a cure. #BTSM #braintumor 

With the focus and dedication of the entire Novocure team, we are confident we can deliver on our goals in 2024. We reported financial results for the quarter ended June 30, 2024, including quarterly net revenues of $150 million, up 19% year-over-year. 3,963 patients were using TTFields therapy as of June 30, up 11% compared to the same period in 2023. Positive results of the Phase 3 METIS trial in brain metastases from non-small cell lung cancer were presented at the 2024 American Society of Clinical Oncology (ASCO) annual meeting. “We are eager to deliver on the promise of our clinical and product development pipelines,” said Asaf Danziger, CEO of Novocure. “Later this year, we are awaiting potential regulatory approvals in post-platinum, metastatic non-small cell lung cancer. We are also hopeful for the read-out of the Phase 3 PANOVA-3 trial in locally advanced pancreatic cancer, and we are launching additional clinical trials that have the potential to dramatically expand the use of TTFields therapy.” Read the Novocure Q2 2024 earnings press release here: https://lnkd.in/dhi8AuBV #earnings #NVCR

With the focus and dedication of the entire Novocure team, we are confident we can deliver on our goals in 2024. We reported financial results for the quarter ended June 30, 2024, including quarterly net revenues of $150 million, up 19% year-over-year. 3,963 patients were using TTFields therapy as of June 30, up 11% compared to the same period in 2023. Positive results of the Phase 3 METIS trial in brain metastases from non-small cell lung cancer were presented at the 2024 American Society of Clinical Oncology (ASCO) annual meeting. “Our glioblastoma business has turned in the best quarter to date, driven by our successful launch in France and improved approval rates in the U.S.,” said Ashley Cordova, Chief Financial Officer at Novocure. “We are now laying the groundwork to launch in post-platinum, metastatic non-small cell lung cancer, pending regulatory approvals, and continue to purposefully invest in clinical research and product innovation.” Read the Novocure Q2 2024 earnings press release here: https://lnkd.in/dhi8AuBV #earnings #NVCR

With the focus and dedication of the entire Novocure team, we are confident we can deliver on our goals in 2024. We reported financial results for the quarter ended June 30, 2024, including quarterly net revenues of $150 million, up 19% year-over-year. 3,963 patients were using TTFields therapy as of June 30, up 11% compared to the same period in 2023. Positive results of the Phase 3 METIS trial in brain metastases from non-small cell lung cancer were presented at the 2024 American Society of Clinical Oncology (ASCO) annual meeting. “We began the year with three key objectives – grow our commercial business in glioblastoma, launch our next indication in non-small cell lung cancer, and deliver on the promise of our clinical and product development pipelines,” said William Doyle, Novocure’s Executive Chairman. “I am pleased to share we have made significant progress on all fronts this quarter and look forward to the challenge of achieving all three goals by year-end.” Read the Novocure Q2 2024 earnings press release here: https://lnkd.in/dhi8AuBV #earnings #NVCR

We are proud to be the presenting sponsor of the national family caregivers self-care series hosted by The EndBrainCancer Initiative - (The Chris Elliott Fund). Founded by Dellann Elliott-Mydland with her late husband Chris, the EndBrainCancer Initiative is led by caregivers. Brain cancer caregivers tirelessly devote time to their loved ones in the face of a diagnosis, and they deserve support and validation. This online event on August 2 offers an opportunity to connect with other GBM caregivers. Learn more and register: https://lnkd.in/d3TEDxz2

DeEtta Ard-McDonald has learned about mutual trust during her long marriage. She views trust as the foundation of all relationships. As a Senior Territory Manager, she establishes trust with medical providers through transparency and open communication about our therapy. Read DeEtta’s story here. https://lnkd.in/eRuNrmxq #oncologysales #medicaldevicesales #patientforward #WeAreNovocure

Congratulations to our 26 Novocure runners from Germany for successfully completing the “B2Run 2024” company running event in Munich! And a big thank you to all the colleagues who cheered for them along the 5.1km (3.1 mile) route through the beautiful Olympic Park. #B2Run #WeAreNovocure

We are at the British Neuro-Oncology Society (BNOS) Annual Meeting 2024 from July 17-19. We are delighted to support and participate in this multidisciplinary, collaborative event that brings together medical and non-medical experts who make a difference for patients with brain cancers.   At Novocure, we are striving to extend survival in some of the most aggressive forms of cancer.   #BNOS2024 #neurooncology #patientforward This message is intended for healthcare professionals in the UK only.

Today marks the sixth annual #GlioblastomaAwarenessDay, where patient advocates come together to support those living with GBM, remember those we have lost, and reaffirm our commitment to developing innovative treatments and, ultimately, a cure for this deadly disease that 15,000 Americans are diagnosed with each year. Mike Ambrogi, Novocure’s Senior Technology Fellow, sat down with Colin Gerner, CPA, President and Co-Founder of StacheStrong, a nonprofit that supports brain tumor patients and their loved ones through research and advocacy. Colin, who lost his older brother GJ to GBM, talked about the profound impact of being present and advocating for those battling this disease.  Through our partnerships with patient advocacy organizations like StacheStrong and continued investment in research and development, we remain committed to supporting the brain tumor community and working towards a day where GBM, at long last, has a cure. https://lnkd.in/dDJt42QY #GBMDay #BTSM

When you build trust with your colleagues, you can help them innovate. That idea drives Zoey Binder, Manager, North America Compliance and Privacy, as she monitors for compliance risks, reviews policies and agreements, and educates colleagues on how to put policies into practice. A law school internship at Novocure sparked Zoey’s interest in compliance. She saw how she could use her legal and interpersonal skills to help a growing business solve problems in compliant ways. The team was welcoming, introducing her to a variety of legal, regulatory and compliance work. “At Novocure, people really foster a positive environment that encourages you to ask questions and learn,” Zoey said. She interned with us a second time and then joined full-time less than a year post-graduation. Today, Zoey connects with colleagues across North America, and she strives to help all (nearly 700) of them do their jobs better. Before someone pursues an idea, her team can help them understand important parameters to follow. “I love being at a company the size of Novocure because I feel like I can actually impact things,” she said. #WeAreNovocure #patientforward #trust #innovation